HC Wainwright Has Lowered Expectations for FibroBiologics (NASDAQ:FBLG) Stock Price

FibroBiologics (NASDAQ:FBLG – Get Free Report) had its price objective decreased by investment analysts at HC Wainwright to $4.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright‘s target price indicates a potential upside of 381.93% from the company’s current price.

FBLG has been the topic of several other reports. Wall Street Zen upgraded shares of FibroBiologics to a “hold” rating in a research report on Saturday, October 10th. Weiss Ratings upgraded shares of FibroBiologics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, September 4th. Finally, Deutsche Bank lowered shares of FibroBiologics to an “underperform” rating in a research report on Tuesday, August 4th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $72.00.

Check Out Our Latest Report on FibroBiologics

FibroBiologics Trading Down 1.2%

Shares of FBLG stock opened at $0.83 on Friday. FibroBiologics has a 1 year low of $0.62 and a 1 year high of $9.60. The firm’s fifty day simple moving average is $1.11 and its 200 day simple moving average is $2.02. The firm has a market capitalization of $5.53 million, a P/E ratio of -0.28 and a beta of 1.81.

FibroBiologics (NASDAQ:FBLG – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.25. Equities research analysts anticipate that FibroBiologics will post -3.00 EPS for the current fiscal year.

Hedge Funds Weigh In On FibroBiologics

An institutional investor recently bought a new position in FibroBiologics stock. IFP Advisors Inc bought a new position in shares of FibroBiologics Inc. (NASDAQ:FBLG – Free Report) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 27,000 shares of the company’s stock, valued at approximately $35,000. IFP Advisors Inc owned approximately 0.41% of FibroBiologics at the end of the most recent quarter.

FibroBiologics Company Profile

(Get Free Report)

FibroBiologics is a clinical-stage biotechnology company developing cell-based therapies for chronic diseases. Its research centers on fibroblasts, cells found in connective tissue that can support tissue repair and other biological processes. The company is developing potential therapies for conditions including multiple sclerosis, degenerative disc disease, wound healing and diabetes. Its programs are investigational, and the company’s approach includes exploring fibroblast cells and related technologies as treatments.

Further Reading

Analyst Recommendations for FibroBiologics (NASDAQ:FBLG)

Receive News & Ratings for FibroBiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroBiologics and related companies with MarketBeat.com's FREE daily email newsletter.